Novartis reports kidney function benefits for IgAN drug in phase III trial
Go back to Novartis reports kidney function benefits for IgAN drug in phase III trial| NOVARTIS AG (NYSE: NVS) | Delayed: 147.08 -3.8 (2.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.88 | 52 Week High | $89.15 | |||
| Open | $149.90 | 52 Week Low | $69.84 | |||
| Day High | $150.08 | P/E | N/A | |||
| Day Low | $146.92 | EPS | $0.00 | |||
| Volume | 1,869,632 | |||||
